Cannon Milani is an Oncology physician. OpenAlex indexes 16 publications with 641 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8950 W Emerald St Ste 108
Boise, ID 837044842
Telephone
208-755-2804Provider last certified this registry record 11 Oct 2025.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SpringWorks Therapeutics, Inc.Program year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20259 payments
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.2%Kinase inhibitor16.5%Imatinib Mesylate29%Lenvima25%Calquence17%Tagrisso17%Brukinsa12%Part D<11 patientsLeukocyte Growth Factor11.2%Nivestym100%Part D≥31 patients+ 4 more classes in this area
Metabolism & gastrointestinal
18.9%Serotonin-3 Receptor Antagonist11.6%Ondansetron Odt75%Ondansetron Hcl25%Part D≥47 patientsProton pump inhibitor3.6%Omeprazole52%Pantoprazole Sodium48%Part D<11 patients+ 2 more classes in this area
Nervous system
16.7%Phenothiazine7.6%Prochlorperazine Maleate100%Part D≥45 patientsGabapentinoids5.9%Gabapentin100%Part D≥21 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma
Leukemia & lymphoma/Leukemia and lymphoma
2010 - Fooled by the fragments: masquerading microangiopathy.
PubMed
2010 - Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
Expert Opinion on Investigational Drugs
2009
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”